Weekly Roundup for NOVEMBER 11, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Every week we review the most recent publications in women’s mental health.
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
Our next course begins on November 14, 2022, and registration is available through the MGH Psych Academy now! This online course will focus on the diagnosis and treatment of psychiatric disorders in women across the [...]
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
Maternal ACEs were associated with both newborn amygdala volume and subsequent infant negative emotionality.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on clinical issues regarding prescribing antidepressants during pregnancy with Ob.Gyn News on August 16, [...]
A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Prenatal cannabis exposure was associated with persisting vulnerability to psychopathology throughout early adolescence.
Family history of psychiatric illness was associated a twofold increased risk for postpartum depression.